Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tetra Bio-Pharma (OP:TBPMF)

N/A UNCHANGED
Last Price Updated: 1:28 PM EDT, Sep 15, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tetra Bio-Pharma

< Previous 1 2 3 4 Next >
Cannabis Stock Movers For July 24, 2023
Via Benzinga
Cannabis Stock Movers For July 21, 2023
Via Benzinga
Akanda To Supply Tetra Bio-Pharma With Cannabis For FDA Trials Of Cancer-Pain Drug
Akanda Corp. 
Via Benzinga
Cannabis Stock Movers For July 20, 2023
Via Benzinga
Cannabis Stock Gainers And Losers From July 18, 2023
Via Benzinga
Cannabis Stock Movers For July 19, 2023
Via Benzinga
Marijuana Stock Movers For July 17, 2023
Via Benzinga
Cannabis Stock Gainers And Losers From July 14, 2023
Via Benzinga
Bullish Thursday For Marijuana Stocks - Choom Holdings, EVIO Among Top Gainers
Via Benzinga
Marijuana Stock Movers For July 12, 2023
Via Benzinga
Cannabis Stock Gainers And Losers From July 11, 2023
Via Benzinga
Tetra Bio-Pharma Receives Funding from the Government of Canada for ARDS-003
The Company is receiving up to $150,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support the development of its novel oral... 
Via TheNewswire.com
Exposures COVID-19
Tetra Bio-Pharma Inc. Announces a Delay in Filing 2022 Annual Financial Statements and Related Management's Discussion and Analysis
MONTREAL, QUEBEC – TheNewswire – March 1, 2023 -- Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTC-PINK: TBPMF) (FRA: JAM1), a leader in cannabinoid-based drug discovery and... 
Via TheNewswire.com
AI Study: Synthetic Cannabinoid + Favipiravir Presents Viable Treatment Against Viral Infections, Including COVID
Tetra Bio-Pharma Inc. (OTCQB: TBPMF) (TSX:TBP) (FRA:JAM1), announced results from the study of Onternabez combined with Favipiravir against ARDS (acute respiratory distress syndrome), sepsis, and... 
Via Benzinga
Tetra Bio-Pharma Announces Second Closing Of Financing With Alpha Blue Ocean
Tetra Bio-Pharma Inc. (OTCQB: TBPMF) (TSX:TBP) (FRA:JAM1), has closed the second tranche of its financing arrangement with Global Corporate Finance Opportunities 16, an investment vehicle advised by... 
Via Benzinga
Preclinical Trial Results Confirm Targeting Type 2 Cannabinoid Receptors Helps Relieve Sepsis-Related Condition
Tetra Bio-Pharma Inc. (OTCQB: TBPMF) (TSX:TBP) (FRA:JAM1) revealed positive preclinical results from live SARS-CoV-2 virus infection studies as well as a septic lung model, carried out by independent... 
Via Benzinga
Akanda to Supply Tetra Bio-Pharma with Pharmaceutical-Grade Cannabis for FDA Trials of QIXLEEF™, a Potential Multimillion Dollar Prescription Drug
From Akanda Corp. and Tetra Bio-Pharma
Via Business Wire
Tetra Bio-Pharma Opens New Subsidiary In Australia And Provides Regulatory Update
Tetra Bio-Pharma Inc. (TSX:TBP) (OTCQB: TBPMF) (FRA:JAM1) launched new wholly owned subsidiary 'Tetra Bio-Pharma Australia Pty Ltd', an Australian-based research company focused on the execution of... 
Via Benzinga
Tetra Bio-Pharma Receives EMA Orphan Drug Designation For A Novel Topical Therapeutic Containing CBD
The European Medicines Agency (EMA) has classified Tetra Bio-Pharma Inc.’s (OTCQB: TBPMF) (TSX:TBP) (FRA:JAM1) PPP004 as an orphan medicinal product for the treatment for epidermolysis bullosa (EB). 
Via Benzinga
Tetra Bio-Pharma And Cannvalate Enter Into Partnership
Tetra Bio-Pharma Inc. (OTCQB: TBPMF) (TSX:TBP) (FRA:JAM1) has entered into a research and development agreement with Cannvalate Pty Ltd for the initiation of the REBORN, PLENITUDE and CAUMZ clinical... 
Via Benzinga
Tetra Bio-Pharma Gets Health Canada's Approval To Use 100mg Of CBD In Inhaled Cannabidiol Safety Study
Health Canada approved the amendment of a phase I study by Tetra Bio-Pharma Inc. (TSX: 
Via Benzinga
Tetra Bio-Pharma Signs License Agreement With Thorne Health Tech For A Prebiotic Dietary Supplement
Tetra Bio-Pharma Inc (TSX:TBP) (OTCQB: 
Via Benzinga
Psychedelic & Marijuana Drug Stocks Continued To Decline Last Week
An update on the stock performances of the 13 clinical-stage psychedelic and marijuana drug companies with the largest market capitalizations.tttttttttt 
Via Talk Markets
Tetra Bio-Pharma Gets CA$4.5M From Québec's Government To Develop Medicine For ARDS
Tetra Bio-Pharma Inc. (TSX:TBP) (OTCQB: 
Via Benzinga
Tetra Bio-Pharma & Avicanna Enter Into Strategic Partnership
Tetra Bio-Pharma Inc. (TSX:TBP) (OTCQB: 
Via Benzinga
Psychedelic And Cannabis Drug Stocks Continue Advance
This article updates the performances of 16 clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses. 
Via Talk Markets
Cannabis Stock Gainers And Losers From January 19, 2022
GAINERS: Heritage Cannabis Holding (OTC: 
Via Benzinga
Cannabis Stock Gainers And Losers From January 18, 2022
GAINERS: Item 9 Labs (OTC: 
Via Benzinga
Marijuana & Psychedelic Drug Stocks Continue To Decline
The Marijuana & Psychedelic Compounds-Based Drug Stocks Index consists of 16 of the 100 such companies that trade on North American stock exchanges. 5 of them are marijuana drug stocks and 11 are... 
Via Talk Markets
Cannabis Stock Gainers And Losers From January 5, 2022
GAINERS: Rhinomed (OTC: 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.